Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder

about

Miliary Tuberculosis that Developed after Intravesical Bacillus Calmette-Guerin Therapy BCG-osis following intravesical BCG treatment leading to miliary pulmonary nodules, penile granulomas and a mycotic aortic aneurysm.

P2860

Q34682234-E5B4A058-89A7-4AD8-83CB-4749F53FAB28 Q40612892-D7404E7E-DFC5-4DC2-A1EE-4453737B8203

P2860

Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder

Item

http://www.wikidata.org/entity/Q39702013

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Subclinical miliary Mycobacter ...... cell carcinoma of the bladder

@en

Subclinical miliary Mycobacter ...... cell carcinoma of the bladder.

@nl

type

Item

label

Subclinical miliary Mycobacter ...... cell carcinoma of the bladder

@en

Subclinical miliary Mycobacter ...... cell carcinoma of the bladder.

@nl

prefLabel

Subclinical miliary Mycobacter ...... cell carcinoma of the bladder

@en

Subclinical miliary Mycobacter ...... cell carcinoma of the bladder.

@nl

P1476

Subclinical miliary Mycobacter ...... cell carcinoma of the bladder

@en

P2093

Chang-Ho Ryan Choi

http://www.w3.org/2001/XMLSchema#string

Geoff Smith

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.

Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer.

Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.

Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.

Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response

Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.

Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

Complications of bacillus Calmette-Guérin immunotherapy.

Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.

Disseminated infection after intravesical BCG immunotherapy. Detection of organisms in pulmonary tissue.

P31

scholarly article

case report

P356

10.1136/BCR-2013-201202

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

Sangoh Lee

P577

2014-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24811557

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

4024537

http://www.w3.org/2001/XMLSchema#string

Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder

about

P2860

P2860

Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P478

P50

P577

P698

P921

P932